ANI Pharmaceuticals reported $217.8M in Cash and Equivalent for its fiscal quarter ending in June of 2025.


Cash And Equivalent Change Date
AbbVie USD 5.18B 349M Mar/2025
ANI Pharmaceuticals USD 217.8M 67.99M Jun/2025
Aurora Cannabis CAD 140.16M 31.45M Jun/2025
Canopy Growth CAD 126.2M 109.89M Jun/2025
Eli Lilly USD 3.38B 282.6M Jun/2025
Hikma Pharmaceutical USD 188M 188M Dec/2024
Knight Therapeutics CAD 5.81M 3.59M Sep/2024
Novartis USD 6.66B 4.8B Jun/2025
Perrigo USD 454.2M 44.3M Jun/2025
Sun Pharmaceuticals INR 113.32B 33.19B Mar/2025
Teva Pharmaceutical Industries USD 2.16B 464M Jun/2025